Boehringer boosts pharma division with key appointment

Lykke Hinsch Gylvin

Boehringer Ingelheim has appointed Lykke Hinsch Gylvin as Head of Medicine and Chief Medical Officer, effective November 1, 2022.

Most recently, Gylvin served as Vice President, Global Medical Franchise Head, Neuroscience at Novartis. She brings more than 20 years of pharmaceutical experience, ranging from early-stage drug development to post-approval lifecycle management. 

During her career, Gylvin has held several global and regional senior leadership roles at companies such as AstraZeneca, Roche, and recently Novartis.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free